The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study - Report - MDSpire

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study

  • By

  • Aspasia Manta

  • Afroditi Roumpou

  • Maria Gerogianni

  • Roubini Zakopoulou

  • Kimon Tzannis

  • Areti Mamali

  • Vasiliki Malamatini

  • Konstantina Kakogianni

  • Aristotelis Bamias

  • Melpomeni Peppa

  • June 30, 2026

  • 0 min

Share

Clinical Report: Examining the Prognostic Role of Metabolic Syndrome on Survival Rates in Urothelial Carcinoma

Overview

This study investigates the prognostic impact of metabolic syndrome (MetS) on survival outcomes in patients with urothelial carcinoma (UC).

Background

Urothelial carcinoma (UC) is a common malignancy with significant morbidity and mortality. The association between metabolic syndrome (MetS) and cancer outcomes is increasingly recognized, yet its specific impact on UC prognosis remains unclear.

Data Highlights

ParameterValue
Patients with MetS49 (43.8%)
HR for OS with MetS2.04 (p=0.018)
HR for PFS with MetS2.13 (p=0.024)
HR for OS with Diabetes3.33 (p=0.001)
HR for OS with Hypertension1.96 (p=0.039)

Key Findings

  • MetS was present in 43.8% of the UC patient cohort.
  • MetS was associated with poorer overall survival (OS) and progression-free survival (PFS).
  • Diabetes was identified as the strongest individual predictor of adverse outcomes.
  • Hypertension independently predicted worse OS outcomes.
  • Obesity and dyslipidemia were not significantly associated with survival outcomes.

Clinical Implications

The findings highlight the importance of considering metabolic syndrome and its components in the prognosis of patients with urothelial carcinoma.

Conclusion

Metabolic syndrome and its components, particularly diabetes and hypertension, are associated with survival outcomes in urothelial carcinoma patients.

Related Resources & Content

  1. Stratifying Risk in High-Risk Muscle-Invasive Urothelial Carcinoma of the Upper Urinary Tract: A Multi-Center Analysis
  2. Impact of Tumor Site on Survival Rates in Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy
  3. Assessment of Histological Subtypes of Upper Tract Urothelial Carcinoma as Predictors of Outcomes Following Radical Nephroureterectomy
  4. Economic Factors Affecting Survival Rates in Patients with Non-Muscle Invasive Urothelial Carcinoma
  5. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
  6. EAU Guidelines on Muscle-Invasive Bladder Cancer 2025
  7. Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma
  8. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology - PubMed
  9. Checking your browser - reCAPTCHA
  10. Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma - PubMed
  11. White-to-brown adipose switching promotes bladder cancer progression - PubMed
  12. Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis combining bibliometric and meta-analysis approaches | BMC Urology | Springer Nature Link
  13. The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study | ECEESPE2025 | Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course | Endocrine Abstracts

Original Source(s)

The impact of metabolic syndrome on survival outcomes in urothelial carcinoma: a retrospective cohort study

  • by Aspasia Manta, Afroditi Roumpou, Maria Gerogianni, Roubini Zakopoulou, Kimon Tzannis, Areti Mamali, Vasiliki Malamatini, Konstantina Kakogianni, Aristotelis Bamias, Melpomeni Peppa

  • June 30, 2026

Related Content

Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology

Roswell Park Introduces Gyn-Onc Connect Line for Consultation

To better service community practitioners, Roswell Park Comprehensive Cancer Center is proud to introduce Gyn-Onc Connect, a dedicated phone number to access Roswell Park’s gynecologic oncology team.

  • by

  • June 29, 2026

  • 1 min
Diagnostic performance of multimodal ultrasound-based deep learning models in differentiating benign and malignant thyroid nodules